Prognostic Value of TGF-β Expression in Bladder Cancer: A Systematic Review and Meta-analysis

Overview

Journal Urol Res Pract

Specialty Urology

Date 2024 Nov 4

PMID 39495544

Authors

Shima Kianmehr

Mohammad Vahabirad

Atefeh Seghatoleslam

Erfan Sadeghi

Roozbeh Kiani

Hadi Ghasemi

Affiliations

Soon will be listed here.

Abstract

Objective: Transforming growth factor beta (TGF-β) is a member of the growth factor superfamily that clinical studies address its association with bladder cancer invasion, progression, and metastasis. The present systematic review and meta-analysis aimed to explore the prognostic significance of TGF-β expression in bladder cancer patients.

Materials And Methods: The major international databases, including PubMed, Web of Science, Embase, and Scopus, were searched for full-text literature citations. The hazard ratio (HR) with a 95% CI as the effect size was applied as the appropriate summarized statistic. We used a random-effects model using the DerSimonian and Laird method to estimate the pooled effect size. To assess the heterogeneity among trials, the I-square (I 2 ) statistic and Cochran's Q test were used. Forest and funnel plots were drawn to respectively demonstrate the findings and detect any existing publication bias.

Results: This meta-analysis included 3 studies that met the criteria and included 535 patients. The combined HR for the selected studies was 2.250 (95% CI=(1.411, 3.586), P< .001) and no significant heterogeneity was detected between trials (I 2=58.63, P=.089). Furthermore, no severe asymmetry was seen within the funnel plot, indicating a lack of potential publication bias.

Conclusion: Our findings suggest that TGF-β expression can remarkably predict a worse prognosis in patients with bladder cancer. The results of the present meta-analysis may be validated through further updated reviews and additional relevant investigations in future studies.

References

Ashrafizadeh M, Najafi M, Orouei S, Zabolian A, Saleki H, Azami N . Resveratrol Modulates Transforming Growth Factor-Beta (TGF-β) Signaling Pathway for Disease Therapy: A New Insight into Its Pharmacological Activities. Biomedicines. 2020; 8(8). PMC: 7460084. DOI: 10.3390/biomedicines8080261. View

Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R . Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg. 2009; 33(7):1439-45. DOI: 10.1007/s00268-009-0070-y. View

Giannelli G, Villa E, Lahn M . Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res. 2014; 74(7):1890-4. DOI: 10.1158/0008-5472.CAN-14-0243. View

Shi X, Yang J, Deng S, Xu H, Wu D, Zeng Q . TGF-β signaling in the tumor metabolic microenvironment and targeted therapies. J Hematol Oncol. 2022; 15(1):135. PMC: 9482317. DOI: 10.1186/s13045-022-01349-6. View

Galsky M, Balar A, Black P, Campbell M, Dykstra G, Grivas P . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer. 2021; 9(7). PMC: 8286774. DOI: 10.1136/jitc-2021-002552. View

Hung T, Wang H, Kingsley E, Risbridger G, Russell P . Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. Cancer Lett. 2008; 265(1):27-38. DOI: 10.1016/j.canlet.2008.02.034. View

Patel V, Oh W, Galsky M . Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020; 70(5):404-423. DOI: 10.3322/caac.21631. View

Ghasemi H, Mousavibahar S, Hashemnia M, Karimi J, Khodadadi I, Tavilani H . Transitional cell carcinoma matrix stiffness regulates the osteopontin and YAP expression in recurrent patients. Mol Biol Rep. 2021; 48(5):4253-4262. DOI: 10.1007/s11033-021-06440-8. View

Stojnev S, Krstic M, Kokoris J, Conic I, Petkovic I, Ilic S . Prognostic Impact of Canonical TGF-β Signaling in Urothelial Bladder Cancer. Medicina (Kaunas). 2019; 55(6). PMC: 6630377. DOI: 10.3390/medicina55060302. View

10.

Sylvester R, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins H . European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021; 79(4):480-488. DOI: 10.1016/j.eururo.2020.12.033. View

11.

McConkey D, Choi W, Marquis L, Martin F, Williams M, Shah J . Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009; 28(3-4):335-44. PMC: 5915353. DOI: 10.1007/s10555-009-9194-7. View

12.

Xiong Y, Zhang J, Shi L, Ning Y, Zhu Y, Chen S . NOGO-B promotes EMT in lung fibrosis via MMP14 mediates free TGF-beta1 formation. Oncotarget. 2017; 8(41):71024-71037. PMC: 5642615. DOI: 10.18632/oncotarget.20297. View

13.

Zhang X, Hu L, Yang Q, Qin W, Wang X, Xu C . CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer. Oncogene. 2021; 40(23):3959-3973. DOI: 10.1038/s41388-021-01827-0. View

14.

Meulmeester E, Ten Dijke P . The dynamic roles of TGF-β in cancer. J Pathol. 2010; 223(2):205-18. DOI: 10.1002/path.2785. View

15.

Zhu S, Yu W, Yang X, Wu C, Cheng F . Traditional Classification and Novel Subtyping Systems for Bladder Cancer. Front Oncol. 2020; 10:102. PMC: 7025453. DOI: 10.3389/fonc.2020.00102. View

16.

Yang L, Zhang F, Wang X, Tsai Y, Chuang K, Keng P . A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer. Oncotarget. 2016; 7(34):55543-55554. PMC: 5342435. DOI: 10.18632/oncotarget.10837. View

17.

Naef M, Ishiwata T, Friess H, Buchler M, Gold L, Korc M . Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma. Int J Cancer. 1997; 71(2):131-7. DOI: 10.1002/(sici)1097-0215(19970410)71:2<131::aid-ijc1>3.0.co;2-1. View

18.

Baek J, Morris S, Campbell J, Fausto N, Yeh M, Grady W . TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer. Int J Cancer. 2009; 127(5):1060-71. PMC: 2897914. DOI: 10.1002/ijc.25127. View

19.

Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y . TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012; 209(3):479-94. PMC: 3302232. DOI: 10.1084/jem.20111653. View

20.

Maruyama T, Chen W, Shibata H . TGF-β and Cancer Immunotherapy. Biol Pharm Bull. 2022; 45(2):155-161. DOI: 10.1248/bpb.b21-00966. View